Autism, also referred to as ASD (Autism Spectrum Disorder), is a mental health condition characterized by delayed neural development and the following symptoms:
- Problems with social abilities
- Impaired social interactions (communication)
- Mood alterations
- Repetitive behavior
- Problems with memory, thinking, and speech
It may also lead to various physical symptoms, such as digestive issues, and sleep disorders. According to the Centers for Disease Control (CDC), “Approximately 1 in 54 children in the Unites States are suffering from Autism today.”
Autism: What Is It?
Autism is a congenital (by birth) neurological disorder that significantly affects a child’s personality, speech, and social interaction. Studies have shown that it affects neuron cell connections and their ability to process information. Although the exact causes remain unknown, genetic factors are likely to play a role. Medications (psychoactive drugs or anticonvulsants) and traditional therapies (medical management/educational interventions) do not work well with Autism Spectrum Disorders.
Autism and Stem Cell Therapy
Stem cell therapy is a safe and effective treatment option for autism spectrum disorder. Essentially, stem cell therapy depends on stem cells’ unique ability to positively impact the immune and metabolic systems of the body, as well as their ability to restore damaged tissue. The treatment has a significant impact on every physiological system in the body, including the brain.
Is Stem Cell Therapy Effective in Treating Autism?
Stem cell therapy treats ASD with umbilical cord tissue-derived mesenchymal stem cells (UCTMSCs). Clinical trials have shown that mesenchymal stromal cells (MSCs) reduce the severity of autism by stimulating activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC). The IV administration of these cells helps reduce neuroinflammation and alleviate symptoms.
Based on our clinical experience, stem cell therapy helps to alleviate the following signs and symptoms of autism.
- Improve digestion and increase food tolerance
- A more friendly eye contact (this therapy helps children with autism to begin fixing their gaze)
- Decreases hyperactivity and aggression
- Improve verbal communication skills, listening, compulsive motor behavior, and repetitive behavior
- Increase attention span and concentration
- Enhance motor and self-improvement skills
- Help reduce anxiety related to strangers, bright light, loud noises, and fear of unfamiliar places
- Improve sleep patterns
Is There a Treatment Protocol for Autism at the Stem Cells Transplant Institute?
We don’t use autologous stem cells because most of the patients with autism are children. Instead, our clinic uses allogeneic mesenchymal stem cells (MCSs) from a donated placenta and umbilical cord.
It is a non-invasive technique to get a large number of high-quality MCSs – without doing liposuction or bone marrow biopsy on the child. In autism, both umbilical cord and placenta stem cells provide MCSs with high therapeutic properties,. These cell lines are prepared in our laboratories and then tested by outside parties.
What Are the Benefits of Human Umbilical Cord Mesenchymal Stem Cells?
- In comparison to bone marrow or adipose-derived stem cells, there are plenty of stem cells
- Since hUC-MSC possesses immunosuppressive and immunomodulatory properties, they can be used in any patient without adverse effects, and no Human Leukocyte Antigen (HLA) matching is required.
- Increased proliferative ability compared to autologous adult stem cells
- Regeneration is quick
- Can easily adapt
- They are unaffected by aging process
- They are unaffected by environment toxins
- UMSCs can be administered multiple times within a few days
- Reduces the need for stem cells to be extracted from the patient’s fat or hip bone, thereby reducing recovery time.
umbilical cord donations
How Are the Stem Cells Collected?
Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.
How Are the Stem Cells Administered?
Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.
About the Stem Cells Transplant Institute
Our clinic is located in Costa Rica, which is one of the most popular medical tourism destinations for stem cell therapy. At the Stem Cells Transplant Institute, we have a skilled team of doctors and medical professionals who collect and administer stem cells to treat autism and other conditions. Every patient receives the most cost-effective and top-notch care from our dedicated team.
- Fu et al. Stem cell transplantation therapy in Parkinson’s disease. SpringerPlus (2015) 4:597
- Joyce et al. Mesenchymal stem cell for the treatment of neurodegenerative disease. Regen Med. 2010, November, 5(6)933-946. Doi:10.2217/rme.10.72
- Helena Vilaça-Faria, António J. Salgado and Fábio G. Teixeira Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s disease. Cells2019, 8(2), 118; doi:3390/cells8020118
- Teixeira, F.G.; Carvalho, M.M.; Neves-Carvalho, A.; Panchalingam, K.M.; Behie, L.A.; Pinto, L.; Sousa, N.; Salgado, A.J. Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural/glial proliferation and differentiation. Stem Cell Rev.2015, 11, 288–297. [Google Scholar] [CrossRef] [PubMed]
- Gao, F.; Chiu, S.M.; Motan, D.A.; Zhang, Z.; Chen, L.; Ji, H.L.; Tse, H.F.; Fu, Q.L.; Lian, Q. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis.2016, 7, e2062. [Google Scholar] [CrossRef] [PubMed]
- Joyce, N.; Annett, G.; Wirthlin, L.; Olson, S.; Bauer, G.; Nolta, J.A. Mesenchymal stem cells for the treatment of neurodegenerative disease. Med.2010, 5, 933–946. [Google Scholar] [CrossRef] [PubMed]
- Fraga, J.S.; Silva, N.A.; Lourenco, A.S.; Goncalves, V.; Neves, N.M.; Reis, R.L.; Rodrigues, A.J.; Manadas, B.; Sousa, N.; Salgado, A.J. Unveiling the effects of the secretome of mesenchymal progenitors from the umbilical cord in different neuronal cell populations. Biochimie2013, 95, 2297–2303. [Google Scholar] [CrossRef] [PubMed]
- Ribeiro, C.A.; Fraga, J.S.; Graos, M.; Neves, N.M.; Reis, R.L.; Gimble, J.M.; Sousa, N.; Salgado, A.J. The secretome of stem cells isolated from the adipose tissue and Wharton jelly acts differently on central nervous system derived cell populations. Stem Cell Res. Ther.2012, 3, 18. [Google Scholar] [CrossRef]
- Ribeiro, C.A.; Salgado, A.J.; Fraga, J.S.; Silva, N.A.; Reis, R.L.; Sousa, N. The secretome of bone marrow mesenchymal stem cells-conditioned media varies with time and drives a distinct effect on mature neurons and glial cells (primary cultures). Tissue Eng. Regen. Med.2011, 5, 668–672. [Google Scholar] [CrossRef]
- Salgado, A.J.; Fraga, J.S.; Mesquita, A.R.; Neves, N.M.; Reis, R.L.; Sousa, N. Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. Stem Cells Dev.2010, 19, 1067–1074. [Google Scholar] [CrossRef]
- Martins, L.F.; Costa, R.O.; Pedro, J.R.; Aguiar, P.; Serra, S.C.; Teixeira, F.G.; Sousa, N.; Salgado, A.J.; Almeida, R.D. Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Rep.2017, 7, 4153. [Google Scholar] [CrossRef]
- Serra, S.C.; Costa, J.C.; Assuncao-Silva, R.C.; Teixeira, F.G.; Silva, N.A.; Anjo, S.I.; Manadas, B.; Gimble, J.M.; Behie, L.A.; Salgado, A.J. Influence of passage number on the impact of the secretome of adipose tissue stem cells on neural survival, neurodifferentiation and axonal growth. Biochimie2018, 155, 119–128. [Google Scholar] [CrossRef]
- Assuncao-Silva, R.C.; Mendes-Pinheiro, B.; Patricio, P.; Behie, L.A.; Teixeira, F.G.; Pinto, L.; Salgado, A.J. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie2018, 155, 83–91. [Google Scholar] [CrossRef] [PubMed]